4D MOLECULAR THERAPEUTICS INC. - COMMON STOCK

4D Molecular Therapeutics Reports Financial Results for the First Quarter of 2021 and Provides Operational Highlights

13 May 2021 13:03:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Presents Non-Human Primate Preclinical Data at ASGCT on the 4D-150 Product Candidate for wet AMD and DME

12 May 2021 14:30:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces Collaboration on Leading Machine Learning Technology and Expertise from U.C. Berkeley to Expand Therapeutic Vector Evolution Platform

04 May 2021 13:02:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics to Participate in BofA Securities 2021 Virtual Health Care Conference

30 Apr 2021 04:05:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces Preclinical Data Presentations at ASGCT and ATS Annual Meetings on Three Wholly-Owned Product Candidates from Non-Human Primate Studies

27 Apr 2021 13:31:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Reports Financial Results for the Year Ended December 31, 2020 and Provides Operational Highlights

25 Mar 2021 13:02:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-310 for the Treatment of Fabry Disease

09 Mar 2021 05:03:00 By Nasdaq GlobeNewswire